Keyphrases
Autoimmune
11%
Autosomal Recessive Congenital Ichthyosis
18%
Beneficial Effects
11%
Blaschko
12%
Bullous Pemphigoid
21%
C-reactive Protein
20%
Clinical Manifestations
15%
Cortical Activity
12%
Cutaneous Adverse Drug Reactions (cADRs)
38%
Default Mode Network
20%
Dermatitis
18%
Desmoglein 3
11%
Drug Eruption
30%
Drug-induced Pemphigus
23%
Epidermal Differentiation
11%
Epidermis
16%
Evanescent Wave Spectroscopy
18%
Fourier Transform Infrared Spectroscopy (FT-IR)
11%
Functional Magnetic Resonance Imaging
16%
High-resolution
12%
Human Leukocyte Antigen
10%
Human Skin
10%
Interferon-gamma Release Assay
24%
Interferon-α (IFN-α)
18%
Interferon-γ
18%
Israeli
10%
Jewish Patients
19%
Jews
10%
Lymphocytes
15%
Microsatellite Markers
21%
Mid-infrared
16%
Mucosal Involvement
12%
Mycosis Fungoides
46%
Neuroanatomical Correlates
10%
Optical Fiber
18%
Pachyonychia Congenita
27%
Palmoplantar Keratoderma
19%
Pediatric
24%
Pemphigus
52%
Pemphigus Vulgaris
100%
Poor Response
11%
Release Test
13%
Response Predictors
10%
Response to Treatment
24%
Single Center
11%
Skin Cancer
11%
Skin Diseases
11%
ST18
18%
T Cells
20%
Young children
11%
Medicine and Dentistry
Adverse Drug Reaction
10%
Atopic Dermatitis
9%
Autosomal Recessive Inheritance
18%
B-Cell Lymphoma
18%
Bullous Pemphigoid
18%
C Reactive Protein
18%
Cancer
9%
Capillary Hemangioma
9%
Cardiac Resynchronization Therapy
9%
Cellulitis
9%
Cerebral Hemorrhage
9%
Chronic Kidney Disease
9%
Cohort Analysis
10%
Darier's Disease
11%
Dermatitis
9%
Dermatology
14%
Desmoglein 1
9%
Diffusion MRI
9%
Disease
14%
Diseases
51%
Drug Eruption
20%
Drug Hypersensitivity
18%
Emotional Stress
9%
Fiber Optics
27%
Forkhead Transcription Factor
9%
Gamma Interferon
11%
Hair Follicle
14%
Ichthyosis
21%
Implantable Automatic Defibrillator
9%
In Vitro
20%
Infrared Fiber
9%
Interferon Gamma Release Assay
24%
Lymphocyte
15%
Morphogenesis
11%
Mycosis fungoides
37%
Notch Signaling
9%
Pachyonychia congenita
27%
Palmoplantar Keratoderma
19%
Pediatrics
27%
Pemphigus
39%
Pemphigus vulgaris
20%
Pimecrolimus
9%
Primary Prevention
9%
Propranolol
9%
Rifampicin
9%
Sensitivity and Specificity
9%
Skin Cancer
12%
Synapsin II
9%
T Cell
20%
Tinea Capitis
9%